Table 2:
Multivariable mixed-effects Cox models of event-free survival as a function of RCB
| All patients (n=4607)* | Hormone receptor-negative, HER2-negative (all patients; n=1585)* | Hormone receptor-negative, HER2-positive (all patients; n=522)* | Hormone receptor-negative, HER2-positive (neoadjuvant HER2-targeted; n=440)*† | Hormone receptor-positive, HER2-positive (all patients; n=773)* | Hormone receptor-positive, HER2-positive (neoadjuvant HER2-targeted; n=674)*† | Hormone receptor-positive, HER2-negative (all patients; n=1727)* | |
|---|---|---|---|---|---|---|---|
| RCB | 1·69 (1·55–1·85)‡ | 1·93 (1·74–2·13)‡ | 2·09 (1·73–2·53)‡ | 2·10 (1·68–2·62)‡ | 1·66 (1·45–1·90)‡ | 1·69 (1·45–1·97)‡ | 1·52 (1·36–1·69)‡ |
| Age | 1·00 (0·99–1·00) | 0·99 (0·98–1·00)‡ | 1·00 (0·98–1·02) | 1·00 (0·97–1·03) | 1·00 (0·99–1·02) | 1·00 (0·98–1·02) | 1·00 (0·99–1·01) |
| T category (reference: T2)§ | |||||||
| T0–1 | 1·08 (0·85–1·37) | 1·05 (0·69–1·60) | 1·99 (1·00–3·96) | 2·46 (1·03–5·87)‡ | 0·80 (0·40–1·61) | 0·50 (0·20–1·26) | 1·01 (0·69–1·46) |
| T3 | 1·28 (1·10–1·49)‡ | 1·73 (1·37–2·18)‡ | 1·60 (0·95–2·69) | 1·64 (0·83–3·24) | 1·02 (0·66–1·56) | 0·88 (0·53–1·48) | 1·08 (0·85–1·37) |
| T4 | 1·89 (1·55–2·31)‡ | 1·43 (1·02–2·01)‡ | 1·27 (0·60–2·68) | 2·39 (1·02–5·58)‡ | 3·23 (2·07–5·03)‡ | 2·98 (1·81–4·90)‡ | 2·11 (1·53–2·91)‡ |
| Nodal status (reference: node negativity) | |||||||
| Node positivity | 1·15 (1·00–1·32)‡ | 1·17 (0·94–1·44) | 0·87 (0·52–1·45) | 0·72 (0·38–1·35) | 1·25 (0·84–1·86) | 1·34 (0·85–2·11) | 1·30 (1·04–1·62)‡ |
| Grade (reference: grade 1–2) | |||||||
| Grade 3 | 1·51 (1·33–1·72)‡ | 1·09 (0·85–1·40) | 0·96 (0·58–1·59) | 0·86 (0·46–1·63) | 0·76 (0·55–1·06) | 0·68 (0·46–0·99)‡ | 1·55 (1·27–1·89)‡ |
RCB was analysed as a continuous score, adjusting for age and pretreatment T category, nodal status, and grade (as fixed effects). Hazard ratios (95% CIs) are shown. All p values are shown in the appendix (p 7). RCB=residual cancer burden.
*
Patients with complete covariate data.
†
The subset who received neoadjuvant HER2-targeted therapy as neoadjuvant treatment in combination with chemotherapy.
‡
Indicates significant p values less than 0·05.
§
T2 was used as the reference category due to the small sample size of the T0–1 group (particularly within the HER2-positive subtypes) in view of concern for the stability of the hazard ratio estimates.